Add to a list

Inactive Instrument

PCAS Stock

PCA

FR0000053514

Pharmaceuticals

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

PCAS specializes in developing, manufacturing, and marketing fine and specialty chemicals. Sales are distributed by family of products as follows: - synthesized pharmaceutical products (63.5%); - fine chemicals (36.5%): technical fluids and additives for the lubricant industry, chemical additive synthesis. The group also offers photochemical and new technology products (photosensitive materials, photo-initiators, and polymers for photography, reprography, and micro-electronics). At the end of 2022, the group had 7 production sites located in France (5), Canada and Finland. France accounts for 76% of net sales.

Employees

1,178

Sector

Pharmaceuticals

More about the company

- 40% : Our Best Subscriber-Only Tools to Spot Tomorrows Top Investments!

SEIZE THE OFFER!

09/02/24	Orapi: takeover bid reopens on February 12
02/02/24	Orapi: 3.15 million shares tendered to the takeover bid
22/12/23	Orapi: takeover bid opens on December 27
19/12/23	PCAS: 200 ME capital increase
03/11/23	PCAS: OPAS to start this Friday
25/10/23	PCAS Announces the Consolidated Net Sales Results for the Month of September 30, 2023	CI
17/10/23	Progyny, Inc. : Want to have a baby?
07/09/23	PCAS: Seqens launches minority share offer
06/09/23	PCAS SA Reports Earnings Results for the Half Year Ended June 30, 2023	CI
28/07/23	PCAS SA Reports Consolidated Sales Results for the Period Ended June 30, 2023	CI
01/06/23	DIC Corporation completed the acquisition of PCAS Canada Inc. from PCAS SA.	CI
25/05/23	PCAS: sale of Canadian subsidiary confirmed
25/05/23	PCAS to Divest Canadian Arm to Japan's DIC	MT

25/10/23	PCAS: Net Sales as of September 30, 2023	GL
07/09/23	PCAS: RESULTS AS OF JUNE 30, 2023	GL
28/07/23	Pcas: Net sales as of June 30, 2023	GL
25/05/23	PCAS to sell its Canadian subsidiary, PCAS Canada Inc., to DIC Corporation	GL
03/05/23	PCAS enters into exclusive negotiations with DIC Corporation following receipt of an offer for the acquisition of its Canadian subsidiary, PCAS Canada Inc.	GL

09/02/24	Orapi : l'OPA réouvre le 12 février
02/02/24	Orapi : 3,15 millions d'actions apportées à l'OPA
05/01/24	Progyny, Inc.: ¿Quieres tener un bebé?
22/12/23	Orapi : l'OPA démarre le 27 décembre
19/12/23	PCAS : augmentation de capital de 200 ME

Manager	Title	Age	Since
Gildas Barreyre CEO	Chief Executive Officer	43	03/05/2025
Eric Moissenot DFI	Director of Finance/CFO	-	-
Gérard Guillamot CTO	Chief Tech/Sci/R&D Officer	-	01/03/1999

Director	Title	Age	Since
Jacqueline Lecourtier BRD	Director/Board Member	74	01/03/2014
Janine Cossy BRD	Director/Board Member	-	-

PCAS Stock

Stocks

PCA

FR0000053514

Pharmaceuticals

Latest news : PCAS

Press Releases: PCAS

News in other languages: PCAS

Managers and Directors: PCAS

Other Pharmaceuticals

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
PCAS	-.--%	-.--%	-	-	125M
ELI LILLY AND COMPANY	-2.41%	+0.14%	+39.53%	+154.43%	1,035B
JOHNSON & JOHNSON	+1.07%	+3.48%	+53.75%	+50.64%	574B
ABBVIE INC.	+1.32%	+0.22%	+18.35%	+65.35%	397B
ROCHE HOLDING AG	+0.58%	+0.77%	+21.19%	+15.95%	324B
ASTRAZENECA PLC	-0.85%	-0.68%	+23.44%	+14.94%	281B
NOVARTIS AG	+0.44%	+5.39%	+25.86%	+35.39%	278B
NOVO NORDISK A/S	+1.66%	+1.20%	-44.41%	-47.37%	193B
AMGEN INC.	+0.32%	+1.61%	+19.48%	+63.42%	191B
GILEAD SCIENCES, INC.	-0.22%	-2.76%	+12.08%	+61.30%	156B
Average	+0.23%	+1.68%	+18.81%	+46.00%	381.1B
Weighted average by Cap.	-0.24%	+2.39%	+28.20%	+71.91%